While framed as a technical regulatory update, the FDA Modernization Act 3.0 advances the misleading narrative that animal research is obsolete and unnecessary. By replacing references to “animal” testing in FDA regulations with broader “nonclinical” terminology, the bill reinforces ongoing activist efforts to marginalize scientifically necessary animal studies.

Animal research remains critical for understanding complex biological systems and developing treatments for cancer, Alzheimer’s disease, infectious diseases, neurological disorders, and other serious conditions. FDA continues to acknowledge that animal data are still required in many areas where validated alternatives do not yet exist.

Although emerging technologies such as AI modeling, organoids, and organ-on-chip systems are promising complementary tools, they cannot fully replicate the complexity of living organisms. Premature efforts to displace animal research risk weakening drug safety evaluation, slowing medical innovation, increasing regulatory uncertainty, and driving research overseas.

The United States should support scientific advancement and development of new methods without undermining the essential role animal research continues to play in protecting public health and advancing lifesaving therapies.